Term,Overlap,P-value,Adjusted P-value,Old P-value,Old Adjusted P-value,Odds Ratio,Combined Score,Genes
Pathways in cancer,62/531,3.61E-27,9.28E-25,0,0,6.587717882,401.1013004,RET;ALK;FLT4;LAMC1;FGF1;BRCA2;FGF2;FGF7;CCND2;MECOM;CCND1;RAC3;ELOB;TPM3;HGF;PRKCA;MITF;FOS;TGFBR2;CCNA2;CCNE2;KIT;RARB;PPARG;MET;EPAS1;LAMA1;PDGFA;CXCR4;PTGS2;IL2RG;PLD1;FOXO1;ADCY5;GNG2;TERT;GNG7;ERBB2;E2F1;E2F2;PMAIP1;BAK1;FADD;RXRG;RUNX1T1;STAT5A;STAT5B;ARNT2;TCF7L2;JUN;STAT1;CDKN2A;ESR1;AGT;GADD45G;GNG13;BMP2;IL6;CXCL12;RAD51;FGFR4;FGFR3
Focal adhesion,30/201,1.46E-16,1.88E-14,0,0,8.194462059,298.773482,SHC3;LAMA1;FLT4;PDGFA;LAMC1;MYLK;VTN;CCND2;CCND1;ERBB2;KDR;RAC3;FLNC;PAK3;PAK5;PAK4;VAV3;JUN;VWF;CAV2;HGF;CAV1;PRKCA;PARVA;VAV2;PPP1CA;COL1A1;COL1A2;COL2A1;MET
Transcriptional misregulation in cancer,29/192,3.43E-16,2.94E-14,0,0,8.293534686,295.3268918,PDGFA;SIX1;FOXO1;HOXA10;CCND2;BAK1;RXRG;RUNX1T1;NGFR;ARNT2;MEF2C;CDKN2C;LMO2;HMGA2;PAX3;GZMB;MITF;RUNX2;FLI1;GADD45G;TGFBR2;CCNA2;PER2;IL6;MYCN;WT1;PPARG;ERG;MET
Human T-cell leukemia virus 1 infection,28/219,8.49E-14,5.45E-12,0,0,6.807437819,204.8855829,NRP1;IL2RG;ETS2;ADCY5;CDC20;CCNB2;ZFP36;CCND2;TERT;CCND1;CHEK1;E2F1;E2F2;STAT5A;EGR1;STAT5B;EGR2;JUN;CDKN2C;CDKN2A;FOS;TGFBR2;CCNA2;IL6;CCNE2;LTA;CALR;MAD2L1
MAPK signaling pathway,32/294,1.32E-13,6.81E-12,0,0,5.705561614,169.1834334,FLT4;PDGFA;FGF1;FGF2;RPS6KA3;FGF7;MECOM;STMN1;ERBB2;KDR;RAC3;FLNC;NGFR;MEF2C;JUN;DUSP1;HGF;PLA2G4A;PRKCA;FOS;MAPK8IP2;GADD45G;CDC25B;TGFBR2;NR4A1;EFNA3;KIT;MAPKAPK2;TEK;FGFR4;FGFR3;MET
PI3K-Akt signaling pathway,34/354,8.39E-13,3.59E-11,0,0,4.972551703,138.2703031,LAMA1;FLT4;PDGFA;BRCA1;LAMC1;FGF1;IL2RG;FGF2;VTN;FGF7;CCND2;GNG2;CCND1;GNG7;ERBB2;KDR;NGFR;VWF;HGF;PRKCA;GNG13;COL1A1;NR4A1;EFNA3;IL6;COL1A2;COL2A1;CCNE2;KIT;TEK;SGK1;FGFR4;FGFR3;MET
Ras signaling pathway,27/232,2.32E-12,8.50E-11,0,0,6.096977477,163.3452472,SHC3;FLT4;PDGFA;FGF1;PLD1;FGF2;ETS2;FGF7;GNG2;GNG7;KDR;RAC3;PAK3;PAK5;PAK4;NGFR;HGF;PLA2G2A;PLA2G4A;PRKCA;GNG13;EFNA3;KIT;TEK;FGFR4;FGFR3;MET
Non-small cell lung cancer,16/72,3.63E-12,1.17E-10,0,0,12.98634699,342.0893211,ALK;RET;STAT5A;STAT5B;CDKN2A;HGF;PRKCA;GADD45G;CCND1;ERBB2;E2F1;RARB;E2F2;BAK1;MET;RXRG
Cell cycle,20/124,4.14E-12,1.18E-10,0,0,8.801357466,230.6854193,CDKN2C;CDKN2A;CDC7;PKMYT1;CDC25B;GADD45G;CDC20;CCNA2;CCNB2;CCND2;DBF4;CCND1;CCNE2;CHEK1;E2F1;MCM4;E2F2;E2F5;BUB1;MAD2L1
Rap1 signaling pathway,23/210,3.44E-10,8.19E-09,0,0,5.644929924,123.0100964,VAV3;NGFR;HGF;FLT4;PDGFA;PRKCA;FGF1;FGF2;VAV2;ADCY5;FGF7;EFNA3;PARD6B;KIT;KDR;RAC3;EVL;PRKD1;TEK;FGFR4;FGFR3;MET;SKAP1
Chemokine signaling pathway,22/192,3.50E-10,8.19E-09,0,0,5.930607704,129.1218116,VAV3;CCL14;STAT5B;CCL13;SHC3;CCL21;STAT1;CXCR4;GNG13;VAV2;ADCY5;CXCL10;GRK3;CXCL12;GNG2;GRK5;GNG7;CXCR2;RAC3;CCL2;CCL19;CCL16
Complement and coagulation cascades,15/85,5.56E-10,1.19E-08,0,0,9.71013289,206.932423,CR1;VWF;SERPINC1;PROS1;F12;PLAUR;F13A1;C4B;C3;C4A;VTN;PROC;SERPING1;A2M;F2RL2
AGE-RAGE signaling pathway in diabetic complications,16/100,6.71E-10,1.33E-08,0,0,8.645132645,182.6074703,STAT5A;EGR1;STAT5B;JUN;STAT1;PRKCA;SELE;FOXO1;AGT;TGFBR2;COL1A1;IL6;COL3A1;COL1A2;CCND1;CCL2
Breast cancer,19/147,7.29E-10,1.34E-08,0,0,6.769237823,142.4176404,TCF7L2;JUN;SHC3;FLT4;BRCA1;FOS;FGF1;BRCA2;FGF2;ESR1;GADD45G;FGF7;CCND1;KIT;ERBB2;E2F1;TNFSF11;E2F2;BAK1
Pancreatic cancer,14/76,1.16E-09,1.98E-08,0,0,10.21263378,210.1046037,CDKN2A;STAT1;BRCA2;PLD1;TGFBR2;GADD45G;RAD51;CCND1;ERBB2;E2F1;RAC3;E2F2;BAK1;ARHGEF6
Proteoglycans in cancer,22/205,1.23E-09,1.98E-08,0,0,5.505613042,112.9450694,VAV3;CAV2;HGF;CAV1;PLAUR;PRKCA;HOXD10;FGF2;ESR1;DCN;VAV2;PPP1CA;COL1A1;VTN;COL1A2;CCND1;ERBB2;KDR;SDC1;FLNC;EZR;MET
Kaposi sarcoma-associated herpesvirus infection,21/193,2.29E-09,3.46E-08,0,0,5.581436485,111.0441433,TCF7L2;JUN;STAT1;FOS;PTGS2;FGF2;GNG13;C3;RCAN1;ZFP36;IL6;GNG2;CCND1;GNG7;MAPKAPK2;IRF7;E2F1;E2F2;FADD;BAK1;IKBKE
Calcium signaling pathway,23/240,4.71E-09,6.73E-08,0,0,4.856989975,93.12133268,RET;PDE1A;HGF;FLT4;PDGFA;CXCR4;PRKCA;ADRB1;ADRB2;GRIN2C;FGF1;FGF2;ADRA1A;MYLK;GRIN2D;FGF7;ITPKA;ERBB2;KDR;CAMK1;FGFR4;FGFR3;MET
Melanoma,13/72,5.92E-09,7.89E-08,0,0,9.943816698,188.3870755,CDKN2A;HGF;PDGFA;MITF;FGF1;FGF2;GADD45G;FGF7;CCND1;E2F1;E2F2;BAK1;MET
Gastric cancer,18/149,6.14E-09,7.89E-08,0,0,6.250460339,118.1893864,TCF7L2;SHC3;HGF;FGF1;FGF2;GADD45G;TGFBR2;FGF7;CCND1;CCNE2;TERT;ERBB2;E2F1;RARB;E2F2;BAK1;MET;RXRG
MicroRNAs in cancer,26/310,7.82E-09,9.57E-08,0,0,4.210612121,78.5987238,PDGFA;IRS2;BRCA1;PTGS2;HOXD10;CCND2;CCND1;STMN1;ERBB2;E2F1;E2F2;BAK1;PAK4;CDKN2A;HMGA2;PRKCA;CDC25B;EFNA3;CCNE2;SPRY2;VIM;EZR;ZFPM2;FGFR3;MET;EZH2
Malaria,Nov-50,1.00E-08,1.17E-07,0,0,12.68320926,233.6291796,IL6;CR1;LRP1;HGF;IL18;PECAM1;CCL2;SDC1;CD36;MET;SELE
Epstein-Barr virus infection,20/202,2.78E-08,3.11E-07,0,0,5.009179056,87.14977398,JUN;STAT1;TAP1;GADD45G;SAP30;CCNA2;CXCL10;IL6;CCND2;CCND1;CCNE2;IRF7;E2F1;E2F2;FADD;CALR;BAK1;VIM;NFKBIE;IKBKE
Prolactin signaling pathway,Dec-70,4.20E-08,4.50E-07,0,0,9.316078681,158.2306186,STAT5A;SOCS3;STAT5B;CCND2;SHC3;CCND1;CISH;STAT1;ELF5;TNFSF11;FOS;ESR1
Viral protein interaction with cytokine and cytokine receptor,14/100,4.60E-08,4.72E-07,0,0,7.353531538,124.2416488,CCL14;CCL13;CCL21;IL18;CXCR4;IL2RG;CXCL10;IL6;CXCL12;CXCR2;LTA;CCL2;CCL19;CCL16
Human immunodeficiency virus 1 infection,20/212,6.25E-08,6.17E-07,0,0,4.745833333,78.72662692,JUN;CXCR4;TAP1;PRKCA;FOS;GNG13;CCNB2;GNG2;GNG7;CHEK1;CFL1;RAC3;ELOB;FADD;CALR;BAK1;PAK3;PAK5;AP1M2;PAK4
Cellular senescence,17/156,7.60E-08,7.23E-07,0,0,5.548174544,90.94860297,CDKN2A;GATA4;FOXO1;GADD45G;TGFBR2;PPP1CA;CCNA2;CCNB2;IL6;CCND2;CCND1;CCNE2;CHEK1;MAPKAPK2;E2F1;E2F2;E2F5
Regulation of actin cytoskeleton,20/218,9.91E-08,8.82E-07,0,0,4.600594177,74.19238355,CYFIP2;VAV3;PDGFA;CXCR4;FGF1;FGF2;MYLK;VAV2;PPP1CA;FGF7;CXCL12;CFL1;RAC3;EZR;PAK3;FGFR4;FGFR3;PAK5;ARHGEF6;PAK4
Chemical carcinogenesis,21/239,9.95E-08,8.82E-07,0,0,4.393251255,70.83138868,STAT5A;STAT5B;JUN;PRKCA;ADRB1;FOS;ADRB2;PTGS2;KLF4;FGF2;ESR1;ADCY5;RPS6KA3;FGF7;CCND1;E2F1;TNFSF11;PPARA;KPNA2;IKBKE;RXRG
Human papillomavirus infection,25/331,1.18E-07,1.01E-06,0,0,3.744358855,59.71845767,MAML2;LAMA1;LAMC1;PTGS2;FOXO1;VTN;PARD6B;CCND2;TERT;CCND1;E2F1;FADD;BAK1;IKBKE;TCF7L2;VWF;STAT1;MX1;TUBG1;COL1A1;CCNA2;COL1A2;COL2A1;DLG2;CCNE2
Human cytomegalovirus infection,20/225,1.66E-07,1.38E-06,0,0,4.441893831,69.33235376,CDKN2A;CXCR4;TAP1;PRKCA;PTGS2;GNG13;ADCY5;IL6;CXCL12;GNG2;CCND1;GNG7;CXCR2;E2F1;RAC3;CCL2;E2F2;FADD;CALR;BAK1
Cytokine-cytokine receptor interaction,23/295,2.17E-07,1.74E-06,0,0,3.863857332,59.28736865,CCL14;NGFR;CCL13;CCL21;IL18;CXCR4;LIFR;INHBA;IL2RG;TGFBR2;CXCL10;BMP2;IL6;CXCL12;CXCR2;LEPR;LTA;TNFSF11;CCL2;CCL19;BMPR1B;TNFRSF4;CCL16
Fluid shear stress and atherosclerosis,15/139,5.04E-07,3.81E-06,0,0,5.466335334,79.26243045,MEF2C;JUN;CAV2;DUSP1;CAV1;PDGFA;FOS;SELE;CDH5;KDR;PECAM1;SDC1;RAC3;CCL2;BMPR1B
Measles,15/139,5.04E-07,3.81E-06,0,0,5.466335334,79.26243045,STAT5A;STAT5B;JUN;STAT1;MX1;FOS;IL2RG;IL6;CCND2;CCND1;CCNE2;IRF7;FADD;BAK1;IKBKE
Hepatitis B,16/162,7.07E-07,5.19E-06,0,0,4.95807389,70.21770898,STAT5A;STAT5B;EGR2;JUN;STAT1;PRKCA;FOS;TGFBR2;CCNA2;IL6;CCNE2;IRF7;E2F1;E2F2;FADD;IKBKE
Chronic myeloid leukemia,Nov-76,9.12E-07,6.51E-06,0,0,7.599787309,105.6941744,STAT5A;STAT5B;SHC3;CCND1;MECOM;CDKN2A;E2F1;E2F2;BAK1;TGFBR2;GADD45G
Thyroid cancer,Aug-37,1.24E-06,8.59E-06,0,0,12.3260475,167.6789647,RET;TCF7L2;CCND1;TPM3;PPARG;BAK1;RXRG;GADD45G
Glutamatergic synapse,13/114,1.55E-06,1.05E-05,0,0,5.796250458,77.53319646,GRIA2;PLA2G4A;PRKCA;PLD1;GRIN2C;GNG13;GRIN2D;ADCY5;GRK3;GNG2;GNG7;HOMER3;GRIA4
Viral carcinogenesis,17/203,3.19E-06,2.10E-05,0,0,4.136179781,52.3473202,STAT5A;STAT5B;EGR2;JUN;CDKN2A;H4-16;CDC20;C3;CCNA2;CCND2;CCND1;CCNE2;CHEK1;MAPKAPK2;IRF7;PMAIP1;BAK1
Axon guidance,16/182,3.31E-06,2.13E-05,0,0,4.356222091,54.97018138,NRP1;CXCR4;PRKCA;SEMA3F;RND1;EFNA3;PARD6B;CXCL12;DPYSL2;CFL1;RAC3;BMPR1B;PAK3;MET;PAK5;PAK4
Insulin resistance,12/108,5.14E-06,3.22E-05,0,0,5.617494226,68.41051719,RPS6KA3;SOCS3;IL6;SLC27A6;IRS2;SLC2A4;CD36;PPARA;PPARGC1A;FOXO1;AGT;PPP1CA
Glioma,Oct-75,6.12E-06,3.64E-05,0,0,6.893015031,82.74066516,SHC3;CCND1;CDKN2A;E2F1;PDGFA;E2F2;PRKCA;BAK1;CAMK1;GADD45G
Small cell lung cancer,Nov-92,6.22E-06,3.64E-05,0,0,6.093588212,73.04597079,CCND1;CCNE2;LAMA1;E2F1;RARB;E2F2;LAMC1;BAK1;PTGS2;RXRG;GADD45G
Relaxin signaling pathway,13/129,6.23E-06,3.64E-05,0,0,5.042844029,60.44139386,JUN;SHC3;PRKCA;FOS;GNG13;TGFBR2;ADCY5;COL1A1;ACTA2;COL3A1;COL1A2;GNG2;GNG7
FoxO signaling pathway,13/131,7.39E-06,4.20E-05,0,0,4.956862053,58.56971984,PLK4;IRS2;SLC2A4;FOXO1;GADD45G;TGFBR2;CCNB2;IL6;CCND2;CCND1;S1PR1;HOMER3;SGK1
TNF signaling pathway,12/112,7.52E-06,4.20E-05,0,0,5.391685912,63.61264631,SOCS3;CXCL10;JUN;IL6;MMP14;BCL3;LTA;CCL2;FADD;FOS;PTGS2;SELE
Circadian entrainment,Nov-97,1.04E-05,5.70E-05,0,0,5.737836245,65.82125884,PER2;GRIA2;GNG2;GNG7;PRKCA;FOS;GRIN2C;GRIA4;GNG13;GRIN2D;ADCY5
Adipocytokine signaling pathway,Sep-69,2.14E-05,1.10E-04,0,0,6.706995413,72.1087078,SOCS3;LEPR;IRS2;SLC2A4;CD36;PPARA;NFKBIE;PPARGC1A;RXRG
Amphetamine addiction,Sep-69,2.14E-05,1.10E-04,0,0,6.706995413,72.1087078,GRIA2;JUN;PRKCA;FOS;GRIN2C;ADCY5;GRIA4;GRIN2D;PPP1CA
Renal cell carcinoma,Sep-69,2.14E-05,1.10E-04,0,0,6.706995413,72.1087078,ARNT2;JUN;EPAS1;HGF;ELOB;PAK3;MET;PAK5;PAK4
"Parathyroid hormone synthesis, secretion and action",11/106,2.44E-05,1.23E-04,0,0,5.191850594,55.15145135,EGR1;MEF2C;MMP14;TNFSF11;PRKCA;GATA3;FOS;PLD1;RXRG;RUNX2;ADCY5
Th17 cell differentiation,11/107,2.66E-05,1.31E-04,0,0,5.1375048,54.11894746,STAT5A;STAT5B;JUN;IL6;STAT1;GATA3;FOS;NFKBIE;IL2RG;RXRG;TGFBR2
Adherens junction,Sep-71,2.71E-05,1.31E-04,0,0,6.489974845,68.25712464,TCF7L2;PTPRB;ERBB2;RAC3;MET;SSX2IP;NECTIN3;NECTIN2;TGFBR2
cAMP signaling pathway,16/216,2.87E-05,1.37E-04,0,0,3.609324009,37.74434373,VAV3;GRIA2;JUN;ADRB1;FOS;ADRB2;GRIN2C;PLD1;SSTR2;GRIN2D;VAV2;ADCY5;PPP1CA;RAC3;PPARA;GRIA4
JAK-STAT signaling pathway,13/162,7.08E-05,3.31E-04,0,0,3.919307731,37.45109446,STAT5A;STAT5B;CISH;STAT1;PDGFA;LIFR;IL2RG;GFAP;SOCS3;IL6;CCND2;CCND1;LEPR
Progesterone-mediated oocyte maturation,10/100,7.80E-05,3.58E-04,0,0,4.971902937,47.02696285,CCNA2;RPS6KA3;CCNB2;KIF22;PKMYT1;BUB1;CDC25B;ADCY5;AURKA;MAD2L1
Lipid and atherosclerosis,15/215,1.00E-04,4.51E-04,0,0,3.375872093,31.09081858,VAV3;JUN;IL18;PRKCA;FOS;SELE;VAV2;IL6;IRF7;CCL2;PPARG;CD36;APOB;IKBKE;RXRG
Hepatocellular carcinoma,13/168,1.03E-04,4.55E-04,0,0,3.766427718,34.59368734,TCF7L2;SHC3;CDKN2A;HGF;PRKCA;GADD45G;TGFBR2;CCND1;TERT;E2F1;E2F2;BAK1;MET
ErbB signaling pathway,Sep-85,1.14E-04,4.96E-04,0,0,5.290650652,48.04677547,STAT5A;STAT5B;JUN;SHC3;ERBB2;PRKCA;PAK3;PAK5;PAK4
Acute myeloid leukemia,Aug-67,1.17E-04,4.99E-04,0,0,6.049257263,54.78773924,CCNA2;STAT5A;PER2;STAT5B;TCF7L2;CCND1;KIT;RUNX1T1
Colorectal cancer,Sep-86,1.25E-04,5.25E-04,0,0,5.221672823,46.94519709,TCF7L2;JUN;CCND1;RAC3;PMAIP1;FOS;BAK1;TGFBR2;GADD45G
Influenza A,13/172,1.30E-04,5.39E-04,0,0,3.670917773,32.84560277,STAT1;MX1;IL18;PRKCA;SOCS3;CXCL10;IL6;IRF7;CCL2;FADD;BAK1;KPNA2;IKBKE
ECM-receptor interaction,Sep-88,1.49E-04,6.07E-04,0,0,5.088955987,44.84611511,COL1A1;VTN;COL2A1;COL1A2;VWF;LAMA1;SDC1;LAMC1;CD36
Oxytocin signaling pathway,12/154,1.76E-04,7.07E-04,0,0,3.788764922,32.75069488,RCAN1;MEF2C;JUN;CCND1;PLA2G4A;PRKCA;FOS;CAMK1;PTGS2;MYLK;ADCY5;PPP1CA
Vascular smooth muscle contraction,11/133,1.93E-04,7.65E-04,0,0,4.037225202,34.51938745,ACTA2;PPP1R14A;PLA2G2A;PLA2G4A;PRKCA;ADRA1A;RAMP1;AGT;MYLK;ADCY5;PPP1CA
Th1 and Th2 cell differentiation,Sep-92,2.09E-04,8.09E-04,0,0,4.842710291,41.02492683,STAT5A;STAT5B;JUN;MAML2;STAT1;FOS;GATA3;IL2RG;NFKBIE
Hepatitis C,12/157,2.11E-04,8.09E-04,0,0,3.709803297,31.39875041,SOCS3;CXCL10;CCND1;STAT1;MX1;IRF7;E2F1;E2F2;FADD;BAK1;PPARA;IKBKE
p53 signaling pathway,Aug-73,2.14E-04,8.09E-04,0,0,5.489174441,46.38253747,CCNB2;CCND2;CCND1;CCNE2;CDKN2A;CHEK1;PMAIP1;GADD45G
Rheumatoid arthritis,Sep-93,2.27E-04,8.47E-04,0,0,4.784813237,40.1408135,JUN;IL6;CXCL12;IL18;CTLA4;TNFSF11;CCL2;FOS;TEK
Coronavirus disease,15/232,2.31E-04,8.48E-04,0,0,3.108670025,26.02885132,NRP1;JUN;VWF;STAT1;MX1;F13A1;PRKCA;FOS;C4B;C3;C4A;CXCL10;IL6;CCL2;IKBKE
IL-17 signaling pathway,Sep-94,2.47E-04,8.92E-04,0,0,4.728278467,39.28290844,CXCL10;JUN;IL6;CCL2;FOS;FADD;PTGS2;IKBKE;MAPK15
Bladder cancer,Jun-41,2.73E-04,9.60E-04,0,0,7.622518711,62.56217229,CCND1;CDKN2A;ERBB2;E2F1;E2F2;FGFR3
Homologous recombination,Jun-41,2.73E-04,9.60E-04,0,0,7.622518711,62.56217229,BARD1;BLM;RAD51;BRCA1;BRCA2;RAD54B
Pertussis,Aug-76,2.83E-04,9.84E-04,0,0,5.246197335,42.85796671,C4B;C3;C4A;JUN;IL6;CFL1;SERPING1;FOS
Hippo signaling pathway,12/163,2.99E-04,0.001022867,0,0,3.561292691,28.90606332,YAP1;TCF7L2;BMP2;PARD6B;CCND2;DLG2;CCND1;FGF1;BMPR1B;TEAD1;TGFBR2;PPP1CA
Prostate cancer,Sep-97,3.12E-04,0.001056393,0,0,4.566383445,36.85636572,TCF7L2;CCND1;CCNE2;ERBB2;E2F1;PDGFA;E2F2;ERG;FOXO1
"Growth hormone synthesis, secretion and action",10/119,3.30E-04,0.001101236,0,0,4.101233787,32.87792004,STAT5A;SOCS3;STAT5B;SHC3;STAT1;IRS2;PRKCA;FOS;SSTR2;ADCY5
Apoptosis,11/142,3.42E-04,0.00112715,0,0,3.758117283,29.99139428,SPTA1;NGFR;JUN;PARP1;PMAIP1;GZMB;FADD;FOS;BAK1;GADD45G;LMNB1
AMPK signaling pathway,10/120,3.53E-04,0.001148159,0,0,4.063740857,32.30358476,CCNA2;CCND1;LEPR;IRS2;PPARG;SLC2A4;CD36;PPARGC1A;ADRA1A;FOXO1
NF-kappa B signaling pathway,9/104,5.24E-04,0.001662628,0,0,4.228392081,31.9412009,CCL13;CXCL12;PARP1;CCL21;LTA;TNFSF11;CCL19;PTGS2;GADD45G
T cell receptor signaling pathway,9/104,5.24E-04,0.001662628,0,0,4.228392081,31.9412009,VAV3;JUN;CTLA4;FOS;NFKBIE;PAK3;PAK5;VAV2;PAK4
Oocyte meiosis,10/129,6.27E-04,0.001964157,0,0,3.754660485,27.6908054,CDC20;RPS6KA3;CCNB2;CCNE2;PKMYT1;BUB1;ADCY5;AURKA;PPP1CA;MAD2L1
Morphine addiction,Aug-91,9.56E-04,0.002960301,0,0,4.294780954,29.86032244,GRK3;GNG2;GRK5;PDE1A;GNG7;PRKCA;ADCY5;GNG13
Apelin signaling pathway,10/137,9.99E-04,0.003020721,0,0,3.516698344,24.29575994,ACTA2;EGR1;MEF2C;GNG2;CCND1;GNG7;PPARGC1A;MYLK;GNG13;ADCY5
Yersinia infection,10/137,9.99E-04,0.003020721,0,0,3.516698344,24.29575994,VAV3;RPS6KA3;JUN;IL6;IL18;RAC3;CCL2;FOS;SKAP2;VAV2
Leukocyte transendothelial migration,9/114,0.001017846,0.003041703,0,0,3.823722149,26.34570012,VAV3;CDH5;CXCL12;PECAM1;RHOH;CXCR4;PRKCA;EZR;VAV2
Fanconi anemia pathway,Jun-54,0.001227949,0.00362739,0,0,5.554384966,37.22776391,BLM;RAD51;FANCD2;FANCA;BRCA1;BRCA2
Endocytosis,14/252,0.001619699,0.004730258,0,0,2.636413266,16.94031221,CAV2;CAV1;CBLC;CXCR4;PLD1;IL2RG;TGFBR2;GRK3;PARD6B;GRK5;BIN1;CXCR2;FGFR4;FGFR3
Cell adhesion molecules,10/148,0.001789406,0.005167162,0,0,3.234549392,20.46134352,CDH5;CNTNAP2;VCAN;CNTN1;PECAM1;SDC1;CTLA4;SELE;NECTIN3;NECTIN2
VEGF signaling pathway,Jun-59,0.001951811,0.005573506,0,0,5.029097004,31.37652327,MAPKAPK2;KDR;RAC3;PLA2G4A;PRKCA;PTGS2
Amoebiasis,8/102,0.001997335,0.005579511,0,0,3.790057939,23.55877916,COL1A1;IL6;COL3A1;COL1A2;LAMA1;PRKCA;CTSG;LAMC1
Chagas disease,8/102,0.001997335,0.005579511,0,0,3.790057939,23.55877916,C3;JUN;IL6;CCL2;FADD;CALR;FOS;TGFBR2
Diabetic cardiomyopathy,12/203,0.002044359,0.005649464,0,0,2.809668331,17.39935198,COL1A1;COL3A1;COL1A2;PARP1;CMA1;PRKCA;CD36;SLC2A4;PPARA;AGT;PPP1CA;TGFBR2
Osteoclast differentiation,9/127,0.002163051,0.005913872,0,0,3.400190484,20.86437051,SOCS3;JUN;STAT1;SIRPA;TNFSF11;MITF;PPARG;FOS;TGFBR2
C-type lectin receptor signaling pathway,8/104,0.002257798,0.006044314,0,0,3.71071701,22.61075402,EGR2;JUN;IL6;STAT1;MAPKAPK2;BCL3;PTGS2;IKBKE
Toll-like receptor signaling pathway,8/104,0.002257798,0.006044314,0,0,3.71071701,22.61075402,CXCL10;JUN;IL6;STAT1;IRF7;FADD;FOS;IKBKE
Cushing syndrome,10/155,0.002513708,0.00666003,0,0,3.077288942,18.42064049,NR4A1;TCF7L2;CDKN2C;CCND1;CCNE2;CDKN2A;E2F1;E2F2;AGT;ADCY5
Cytosolic DNA-sensing pathway,Jun-63,0.002732446,0.007165701,0,0,4.675218799,27.59575014,CXCL10;IL6;IL18;IRF7;POLR2H;IKBKE
Dopaminergic synapse,9/132,0.002811122,0.007297559,0,0,3.261132244,19.15645041,GRIA2;GNG2;GNG7;PRKCA;FOS;GRIA4;GNG13;ADCY5;PPP1CA
HIF-1 signaling pathway,8/109,0.003026225,0.007777397,0,0,3.526111879,20.45299836,IL6;ERBB2;PRKCA;ELOB;TIMP1;TEK;ENO2;ALDOA
Inflammatory bowel disease,Jun-65,0.003200716,0.008144397,0,0,4.516273503,25.94319426,JUN;IL6;STAT1;IL18;GATA3;IL2RG
Long-term potentiation,Jun-67,0.003726337,0.009388907,0,0,4.36775085,24.42590272,RPS6KA3;GRIA2;PRKCA;GRIN2C;GRIN2D;PPP1CA
Serotonergic synapse,8/113,0.003776183,0.009422127,0,0,3.391086412,18.91901174,GNG2;DUSP1;GNG7;PLA2G4A;PRKCA;PTGS2;GNG13;ADCY5
Neuroactive ligand-receptor interaction,16/341,0.004272736,0.010457973,0,0,2.206777838,12.03907861,OPRD1;GRIA2;ADRB1;ADRB2;GRIN2C;SSTR2;ADRA1A;AGT;GRIN2D;C3;PYY;LEPR;S1PR1;CTSG;F2RL2;GRIA4
cGMP-PKG signaling pathway,10/167,0.004286709,0.010457973,0,0,2.84032506,15.48612237,OPRD1;MEF2C;IRS2;ADRB1;GATA4;ADRB2;ADRA1A;MYLK;ADCY5;PPP1CA
Renin secretion,Jun-69,0.004313405,0.010457973,0,0,4.228658206,23.02938931,PDE1A;ADRB1;ADRB2;AGT;AQP1;ADCY5
Cocaine addiction,May-49,0.004546965,0.010921214,0,0,5.038997934,27.17680414,GRIA2;JUN;GRIN2C;ADCY5;GRIN2D
GnRH signaling pathway,Jul-93,0.004721244,0.011234812,0,0,3.618004672,19.37688584,EGR1;MMP14;JUN;PLA2G4A;PRKCA;PLD1;ADCY5
Dilated cardiomyopathy,Jul-96,0.005614044,0.013236782,0,0,3.495510749,18.11542861,ACTC1;TPM3;LAMA1;ADRB1;DMD;AGT;ADCY5
Thyroid hormone signaling pathway,8/121,0.005699942,0.013317138,0,0,3.149713453,16.27551194,RCAN1;CCND1;STAT1;PRKCA;GATA4;ESR1;RXRG;FOXO1
Fc gamma R-mediated phagocytosis,Jul-97,0.00593801,0.01368115,0,0,3.456494165,17.71930652,VAV3;BIN1;CFL1;PLA2G4A;PRKCA;PLD1;VAV2
Phospholipase D signaling pathway,9/148,0.005962213,0.01368115,0,0,2.883374035,14.76954572,SHC3;KIT;CXCR2;PDGFA;PLA2G4A;PRKCA;PLD1;AGT;ADCY5
Choline metabolism in cancer,Jul-98,0.006275738,0.014273139,0,0,3.41833509,17.33459655,JUN;PDGFA;RAC3;PLA2G4A;PRKCA;FOS;PLD1
Adrenergic signaling in cardiomyocytes,9/150,0.006495732,0.014643886,0,0,2.842182315,14.3149638,ACTC1;TPM3;PRKCA;ADRB1;ADRB2;ADRA1A;AGT;ADCY5;PPP1CA
Platelet activation,8/124,0.006587018,0.014720554,0,0,3.067781899,15.40840851,COL1A1;COL3A1;COL1A2;VWF;PLA2G4A;MYLK;ADCY5;PPP1CA
Leishmaniasis,Jun-77,0.007358795,0.016261897,0,0,3.750649684,18.42266292,C3;JUN;CR1;STAT1;FOS;PTGS2
Regulation of lipolysis in adipocytes,May-55,0.00744423,0.016261897,0,0,4.432954545,21.72287848,IRS2;ADRB1;ADRB2;PTGS2;ADCY5
NOD-like receptor signaling pathway,10/181,0.007466552,0.016261897,0,0,2.605901727,12.76193973,JUN;IL6;STAT1;IL18;IRF7;TXNIP;CCL2;FADD;ANTXR2;IKBKE
DNA replication,Apr-36,0.008113164,0.017521707,0,0,5.533730159,26.64085648,FEN1;RFC4;POLE2;MCM4
African trypanosomiasis,Apr-37,0.008939962,0.019035602,0,0,5.365766509,25.31152212,IL6;IL18;PRKCA;SELE
Alcoholism,10/186,0.008962287,0.019035602,0,0,2.531217346,11.93400582,H2AX;SHC3;GNG2;GNG7;H4-16;GRIN2C;GNG13;GRIN2D;ADCY5;PPP1CA
Endometrial cancer,May-58,0.009290214,0.019551461,0,0,4.181389365,19.56385812,TCF7L2;CCND1;ERBB2;BAK1;GADD45G
B cell receptor signaling pathway,Jun-81,0.009357314,0.019551461,0,0,3.549886105,16.58363729,VAV3;JUN;RAC3;FOS;NFKBIE;VAV2
Salmonella infection,12/249,0.010208267,0.021157458,0,0,2.258952846,10.35629888,CYFIP2;TCF7L2;JUN;IL6;RHOJ;IL18;RHOH;FADD;FOS;FLNC;BAK1;PAK3
Viral myocarditis,May-60,0.010682515,0.02196325,0,0,4.02892562,18.28788574,CCND1;LAMA1;CAV1;RAC3;DMD
Estrogen signaling pathway,8/137,0.011682902,0.023579158,0,0,2.756780728,12.26665113,JUN;KRT19;SHC3;KRT15;FOS;FKBP4;ESR1;ADCY5
Insulin signaling pathway,8/137,0.011682902,0.023579158,0,0,2.756780728,12.26665113,SOCS3;SHC3;PRKAR2B;IRS2;SLC2A4;PPARGC1A;FOXO1;PPP1CA
Nicotine addiction,Apr-40,0.011743705,0.023579158,0,0,4.917863442,21.85713863,GRIA2;GRIN2C;GRIA4;GRIN2D
Wnt signaling pathway,9/166,0.012186303,0.024278139,0,0,2.550429498,11.24087175,TLE4;TCF7L2;JUN;CCND2;CCND1;CTNND2;RUVBL1;RAC3;PRKCA
Cholinergic synapse,7/113,0.013228304,0.026151339,0,0,2.93234686,12.68356292,GNG2;GNG7;PRKCA;KCNQ5;FOS;GNG13;ADCY5
Tight junction,9/169,0.013573178,0.026628297,0,0,2.502221904,10.75870244,JUN;PARD6B;DLG2;CCND1;ERBB2;GATA4;AMOTL2;EZR;MPDZ
Renin-angiotensin system,Mar-23,0.013921405,0.027104554,0,0,6.629524887,28.33676166,CMA1;CTSG;AGT
GABAergic synapse,Jun-89,0.014465207,0.027951566,0,0,3.206411066,13.58238614,GNG2;GNG7;GAD1;PRKCA;ADCY5;GNG13
Signaling pathways regulating pluripotency of stem cells,8/143,0.014825885,0.02843472,0,0,2.633443512,11.090433,LIFR;OTX1;INHBA;BMPR1B;FGFR4;KLF4;FGF2;FGFR3
Type I diabetes mellitus,Apr-43,0.015056526,0.028663165,0,0,4.538868539,19.04483705,PTPRN;GAD1;LTA;GZMB
Hypertrophic cardiomyopathy,Jun-90,0.015217019,0.028755691,0,0,3.168076798,13.25948108,IL6;ACTC1;TPM3;LAMA1;DMD;AGT
Neurotrophin signaling pathway,7/119,0.01715616,0.032183454,0,0,2.774400685,11.27904288,RPS6KA3;NGFR;JUN;SHC3;MAGED1;MAPKAPK2;NFKBIE
Fc epsilon RI signaling pathway,May-68,0.017668707,0.032904765,0,0,3.515873016,14.18992351,VAV3;RAC3;PLA2G4A;PRKCA;VAV2
Retrograde endocannabinoid signaling,8/148,0.017880759,0.033060108,0,0,2.53873815,10.21595862,GRIA2;GNG2;GNG7;PRKCA;PTGS2;GRIA4;GNG13;ADCY5
TGF-beta signaling pathway,Jun-94,0.018495191,0.033951886,0,0,3.02345206,12.06431303,BMP2;INHBA;E2F5;BMPR1B;DCN;TGFBR2
Central carbon metabolism in cancer,May-70,0.019795233,0.036080673,0,0,3.407342657,13.3646682,RET;KIT;ERBB2;MET;FGFR3
Aldosterone synthesis and secretion,Jun-98,0.02222623,0.040226346,0,0,2.891403387,11.00607541,NR4A1;PRKCA;PRKD1;CAMK1;AGT;ADCY5
Non-alcoholic fatty liver disease,8/155,0.022881749,0.041123143,0,0,2.416974112,9.129915894,SOCS3;JUN;IL6;LEPR;IRS2;PPARG;FOS;PPARA
Ether lipid metabolism,Apr-49,0.023311305,0.041604204,0,0,3.932476694,14.78145965,PLA2G2A;PLA2G4A;PLD1;PAFAH1B3
PPAR signaling pathway,May-74,0.024535545,0.043487139,0,0,3.209156785,11.89837364,SLC27A6;PPARG;CD36;PPARA;RXRG
Longevity regulating pathway,6/102,0.026433921,0.046530942,0,0,2.77035877,10.06501045,IRS2;PPARG;PPARGC1A;CRYAB;FOXO1;ADCY5
Gastric acid secretion,May-76,0.027156816,0.047478243,0,0,3.1184379,11.24548378,PRKCA;SSTR2;EZR;MYLK;ADCY5
Natural killer cell mediated cytotoxicity,7/131,0.027350451,0.047493689,0,0,2.504363677,9.013260599,VAV3;SHC3;SH2D1A;RAC3;GZMB;PRKCA;VAV2
Protein digestion and absorption,6/103,0.027562848,0.047541288,0,0,2.741657469,9.846077476,COL17A1;COL1A1;COL3A1;COL1A2;COL2A1;COL8A1
Pathogenic Escherichia coli infection,9/197,0.03265474,0.055948455,0,0,2.126476186,7.276302309,CYFIP2;JUN;IL6;IL18;FADD;FOS;BAK1;EZR;PAK3
Base excision repair,Mar-33,0.036456893,0.06204915,0,0,4.417420814,14.62883997,FEN1;PARP1;POLE2
Ubiquitin mediated proteolysis,7/140,0.037267728,0.063011882,0,0,2.333813987,7.677378743,CDC20;PRKN;SOCS3;CBLC;UBE2L6;ELOB;BRCA1
Legionellosis,Apr-57,0.037897459,0.063657823,0,0,3.337526205,10.92329344,C3;IL6;CR1;IL18
PD-L1 expression and PD-1 checkpoint pathway in cancer,May-89,0.04848648,0.08091575,0,0,2.634063853,7.971915954,ALK;JUN;STAT1;FOS;NFKBIE
Basal cell carcinoma,Apr-63,0.051603205,0.085561444,0,0,2.997194358,8.884198067,TCF7L2;BMP2;BAK1;GADD45G
Salivary secretion,May-93,0.05658924,0.093227145,0,0,2.513817149,7.219523015,PRKCA;ADRB1;ADRB2;ADRA1A;ADCY5
Staphylococcus aureus infection,May-95,0.060915183,0.099714663,0,0,2.45770202,6.877320769,C4B;C3;C4A;KRT19;KRT15
Mitophagy,Apr-68,0.064826976,0.105446411,0,0,2.762329932,7.557827118,PRKN;JUN;E2F1;MITF
Necroptosis,7/159,0.06527233,0.105503074,0,0,2.040089522,5.567785952,STAT5A;H2AX;STAT5B;PARP1;STAT1;PLA2G4A;FADD
Hematopoietic cell lineage,May-99,0.070113846,0.111947308,0,0,2.352635397,6.252446151,IL6;CR1;CD5;KIT;CD36
Fat digestion and absorption,Mar-43,0.070239617,0.111947308,0,0,3.311368778,8.794474853,PLA2G2A;CD36;APOB
RIG-I-like receptor signaling pathway,Apr-70,0.070566007,0.111947308,0,0,2.678348107,7.100854529,CXCL10;IRF7;FADD;IKBKE
Melanogenesis,5/101,0.074984575,0.118227213,0,0,2.303385417,5.966857407,TCF7L2;KIT;MITF;PRKCA;ADCY5
Systemic lupus erythematosus,6/135,0.081337111,0.127461205,0,0,2.058166022,5.164253228,C4B;C3;H2AX;C4A;H4-16;CTSG
Type II diabetes mellitus,Mar-46,0.082371884,0.12830045,0,0,3.079869515,7.688928472,SOCS3;IRS2;SLC2A4
Intestinal immune network for IgA production,Mar-48,0.0909249,0.140769273,0,0,2.942684766,7.055738201,IL6;CXCL12;CXCR4
Bacterial invasion of epithelial cells,Apr-77,0.092600387,0.142504788,0,0,2.420650452,5.759845658,SHC3;CAV2;CAV1;MET
RNA degradation,Apr-79,0.09943092,0.15181228,0,0,2.355857899,5.438008299,EXOSC4;LSM1;ENO2;LSM4
Cholesterol metabolism,Mar-50,0.099829865,0.15181228,0,0,2.817175315,6.491582964,LRP1;CD36;APOB
Ovarian steroidogenesis,Mar-51,0.104408806,0.157841547,0,0,2.75834276,6.232313444,PLA2G4A;PTGS2;ADCY5
alpha-Linolenic acid metabolism,Feb-25,0.105998063,0.15930703,0,0,3.833938561,8.604640426,PLA2G2A;PLA2G4A
Insulin secretion,Apr-86,0.125078692,0.186890836,0,0,2.153973785,4.477706989,RIMS2;RAB3A;PRKCA;ADCY5
Sphingolipid signaling pathway,5/119,0.126599315,0.188069503,0,0,1.937898724,4.005109899,OPRD1;S1PR1;RAC3;PRKCA;PLD1
Hedgehog signaling pathway,Mar-56,0.12847714,0.189762213,0,0,2.497481431,5.124842608,GRK3;CCND2;CCND1
Neutrophil extracellular trap formation,7/189,0.129822932,0.190654249,0,0,1.701176677,3.473094776,C3;H2AX;CR1;VWF;H4-16;PRKCA;CTSG
Gap junction,Apr-88,0.132874611,0.19402713,0,0,2.102472735,4.243524527,PDGFA;PRKCA;ADRB1;ADCY5
Linoleic acid metabolism,Feb-29,0.135540721,0.196802064,0,0,3.265278823,6.525604739,PLA2G2A;PLA2G4A
beta-Alanine metabolism,Feb-30,0.143188072,0.206423596,0,0,3.148500484,6.119413976,ALDH2;GAD1
Notch signaling pathway,Mar-59,0.143773633,0.206423596,0,0,2.363324176,4.583703188,TLE4;MAML2;DTX1
Herpes simplex virus 1 infection,15/498,0.146660389,0.209398444,0,0,1.377437527,2.644178174,STAT1;TAP1;PPP1CA;C3;SOCS3;IL6;IRF7;LTA;CCL2;ZNF205;BAK1;FADD;CALR;IKBKE;NECTIN2
Long-term depression,Mar-60,0.14900103,0.211564999,0,0,2.321743272,4.42013962,GRIA2;PLA2G4A;PRKCA
Arachidonic acid metabolism,Mar-61,0.154288814,0.21786937,0,0,2.281596193,4.264141323,PLA2G2A;PLA2G4A;PTGS2
Riboflavin metabolism,1-Aug,0.164764475,0.230512559,0,0,6.28957529,11.34160272,FLAD1
Lysine degradation,Mar-63,0.165036229,0.230512559,0,0,2.205316742,3.973077161,ALDH2;MECOM;EZH2
Inflammatory mediator regulation of TRP channels,Apr-98,0.174600655,0.242553343,0,0,1.877840498,3.277308422,PLA2G4A;PRKCA;ADCY5;PPP1CA
Cortisol synthesis and secretion,Mar-65,0.175997347,0.24317913,0,0,2.133958546,3.707297072,NR4A1;AGT;ADCY5
Glycolysis / Gluconeogenesis,Mar-67,0.187153841,0.257211429,0,0,2.067060238,3.464029817,ALDH2;ENO2;ALDOA
Aldosterone-regulated sodium reabsorption,Feb-37,0.198779251,0.271735465,0,0,2.517897452,4.067815319,PRKCA;SGK1
Epithelial cell signaling in Helicobacter pylori infection,Mar-70,0.204215484,0.277689838,0,0,1.974201391,3.136175956,JUN;CXCR2;MET
Primary immunodeficiency,Feb-38,0.206933064,0.279904196,0,0,2.447830449,3.856213938,TAP1;IL2RG
Tuberculosis,6/180,0.213156173,0.286812232,0,0,1.522347027,2.353137739,C3;IL6;CR1;STAT1;IL18;FADD
Glucagon signaling pathway,4/107,0.215433664,0.288366936,0,0,1.712964798,2.629576097,PPP4C;PPARA;PPARGC1A;FOXO1
Taurine and hypotaurine metabolism,1-Nov,0.219309085,0.292033341,0,0,4.402027027,6.679077617,GAD1
Graft-versus-host disease,Feb-42,0.239839197,0.317725122,0,0,2.202595937,3.144836949,IL6;GZMB
Arrhythmogenic right ventricular cardiomyopathy,Mar-77,0.245246704,0.32322258,0,0,1.786810566,2.511345488,TCF7L2;LAMA1;DMD
Non-homologous end-joining,Jan-13,0.253682834,0.332635145,0,0,3.66798048,5.031260536,FEN1
Pathways of neurodegeneration,13/475,0.261626204,0.341309312,0,0,1.243631754,1.667509329,PRKN;GRIA2;PRKCA;UBE2L6;GRIN2C;PTGS2;SNCAIP;GRIN2D;IL6;BAK1;FADD;NEFH;GRIA4
Nucleotide excision repair,Feb-47,0.281250702,0.365057729,0,0,1.957361425,2.482930251,RFC4;POLE2
Nitrogen metabolism,Jan-17,0.317965871,0.410639341,0,0,2.750422297,3.151464745,CA12
Autoimmune thyroid disease,Feb-53,0.330658181,0.422781853,0,0,1.726552472,1.910724038,CTLA4;GZMB
Endocrine and other factor-regulated calcium reabsorption,Feb-53,0.330658181,0.422781853,0,0,1.726552472,1.910724038,PRKCA;ESR1
Protein processing in endoplasmic reticulum,5/171,0.332455471,0.422975525,0,0,1.327286418,1.461673305,PRKN;DNAJC1;CALR;BAK1;CRYAB
Pyrimidine metabolism,Feb-56,0.35502894,0.449470136,0,0,1.630382075,1.688351894,NME3;TK1
Glycerophospholipid metabolism,Mar-98,0.372695323,0.46952303,0,0,1.390331031,1.372248416,PLA2G2A;PLA2G4A;PLD1
Pantothenate and CoA biosynthesis,Jan-21,0.376723331,0.47228242,0,0,2.199887387,2.14762737,ALDH2
Histidine metabolism,Jan-22,0.390605789,0.487309164,0,0,2.095023595,1.969440422,ALDH2
Spinocerebellar ataxia,4/143,0.393991928,0.48915906,0,0,1.266970097,1.180087443,GRIA2;PRKCA;GRIN2C;GRIN2D
Pancreatic secretion,3/102,0.39682793,0.490311433,0,0,1.333881804,1.232843616,PLA2G2A;PRKCA;ADCY5
Mismatch repair,Jan-23,0.404179717,0.494273492,0,0,1.999692875,1.811513089,RFC4
Proximal tubule bicarbonate reclamation,Jan-23,0.404179717,0.494273492,0,0,1.999692875,1.811513089,AQP1
Prion disease,7/273,0.405804306,0.494273492,0,0,1.158916126,1.045208189,EGR1;IL6;CAV2;CAV1;LAMC1;GRIN2C;GRIN2D
Vitamin digestion and absorption,Jan-24,0.417451956,0.506062042,0,0,1.912651782,1.670865467,APOB
Phagosome,4/152,0.438944651,0.529618663,0,0,1.189373047,0.979308303,C3;TAP1;CALR;CD36
Maturity onset diabetes of the young,Jan-26,0.443117984,0.53215571,0,0,1.759459459,1.432057861,NR5A2
Toxoplasmosis,3/112,0.455895225,0.544953827,0,0,1.210884636,0.951140516,LAMA1;STAT1;LAMC1
Butanoate metabolism,Jan-28,0.467655639,0.556423608,0,0,1.628962296,1.238048921,GAD1
Ascorbate and aldarate metabolism,Jan-30,0.491114421,0.578974341,0,0,1.516464741,1.078324929,ALDH2
Pentose phosphate pathway,Jan-30,0.491114421,0.578974341,0,0,1.516464741,1.078324929,ALDOA
Thyroid hormone synthesis,Feb-75,0.499739736,0.584301837,0,0,1.204861004,0.835773336,PRKCA;ADCY5
Circadian rhythm,Jan-31,0.502454109,0.584301837,0,0,1.465840841,1.008866379,PER2
RNA polymerase,Jan-31,0.502454109,0.584301837,0,0,1.465840841,1.008866379,POLR2H
Antigen processing and presentation,Feb-78,0.520661673,0.601635487,0,0,1.15712249,0.755201581,TAP1;CALR
Fructose and mannose metabolism,Jan-33,0.524382682,0.601635487,0,0,1.374085023,0.887017987,ALDOA
SNARE interactions in vesicular transport,Jan-33,0.524382682,0.601635487,0,0,1.374085023,0.887017987,STX11
Purine metabolism,3/129,0.550056337,0.628286571,0,0,1.046595561,0.625586354,PDE1A;NME3;ADCY5
"Alanine, aspartate and glutamate metabolism",Jan-37,0.565388963,0.642942316,0,0,1.221158659,0.696355168,GAD1
Taste transduction,Feb-86,0.57352509,0.648222707,0,0,1.046490379,0.581800089,PDE1A;GNG13
Allograft rejection,Jan-38,0.575076954,0.648222707,0,0,1.188093499,0.657314408,GZMB
Cardiac muscle contraction,Feb-87,0.579827373,0.650723297,0,0,1.034125614,0.56362416,ACTC1;TPM3
Bile secretion,Feb-90,0.598322636,0.668560511,0,0,0.998717423,0.512966381,AQP1;ADCY5
Tryptophan metabolism,Jan-42,0.611721383,0.68057314,0,0,1.071962206,0.526846224,ALDH2
Fatty acid degradation,Jan-43,0.620378734,0.687229891,0,0,1.046385671,0.499570811,ALDH2
ABC transporters,Jan-45,0.637119889,0.701894231,0,0,0.998720311,0.450220551,TAP1
Phosphatidylinositol signaling system,Feb-97,0.639078794,0.701894231,0,0,0.924795058,0.414056201,ITPKA;PRKCA
Parkinson disease,5/249,0.652870567,0.711241346,0,0,0.899357303,0.383464713,PRKN;DUSP1;UBE2L6;SNCAIP;ADCY5
Pyruvate metabolism,Jan-47,0.653124349,0.711241346,0,0,0.955199765,0.40690339,ALDH2
"Valine, leucine and isoleucine degradation",Jan-48,0.660860482,0.716629299,0,0,0.934828445,0.387217658,ALDH2
mTOR signaling pathway,3/154,0.669449585,0.722893039,0,0,0.87219442,0.350011114,RPS6KA3;PRKCA;SGK1
Arginine and proline metabolism,Jan-50,0.675820105,0.723690696,0,0,0.896580254,0.351305566,ALDH2
Vibrio cholerae infection,Jan-50,0.675820105,0.723690696,0,0,0.896580254,0.351305566,PRKCA
Drug metabolism,2/108,0.696456054,0.740238597,0,0,0.828357255,0.29965872,NME3;TK1
Glycosaminoglycan biosynthesis,Jan-53,0.697034009,0.740238597,0,0,0.844724532,0.304878887,CHPF
Alzheimer disease,7/369,0.716875472,0.758176939,0,0,0.847341003,0.282040108,IL6;LRP1;IRS2;FADD;GRIN2C;PTGS2;GRIN2D
Glycerolipid metabolism,Jan-61,0.747074343,0.786877484,0,0,0.731794294,0.213384321,ALDH2
Thermogenesis,4/232,0.761819844,0.797780614,0,0,0.768866611,0.209166453,RPS6KA3;PPARG;PPARGC1A;ADCY5
GnRH secretion,Jan-64,0.763634362,0.797780614,0,0,0.696839697,0.187914105,PRKCA
Lysosome,2/128,0.781360981,0.812995029,0,0,0.696155362,0.171754081,CTSG;AP1M2
Shigellosis,4/246,0.800205732,0.829245457,0,0,0.723861997,0.161339008,C3;JUN;IL18;FOXO1
Inositol phosphate metabolism,Jan-73,0.807100127,0.833031055,0,0,0.609453203,0.13061042,ITPKA
Huntington disease,5/306,0.814051632,0.836845078,0,0,0.726895198,0.149545229,GRIA2;PPARG;POLR2H;PPARGC1A;GRIA4
Synaptic vesicle cycle,Jan-78,0.827699915,0.84748557,0,0,0.56973207,0.107738962,RAB3A
Spliceosome,2/150,0.850039168,0.866905024,0,0,0.592001708,0.096184205,SNRPE;LSM4
mRNA surveillance pathway,Jan-98,0.890358265,0.904435075,0,0,0.451797158,0.052467815,PPP1CA
Amyotrophic lateral sclerosis,5/364,0.910401288,0.921154059,0,0,0.607622183,0.057037373,PRKN;GRIA2;GRIN2C;NEFH;GRIN2D
Autophagy,1/137,0.95464719,0.962134619,0,0,0.321591812,0.014926183,IRS2
Olfactory transduction,5/440,0.969214247,0.973000241,0,0,0.499477534,0.015618458,GRK3;PDE1A;GNG7;NCALD;GNG13
RNA transport,1/186,0.985076062,0.985076062,0,0,0.235816898,0.003545842,CYFIP2
